tubulin beta 2A class IIaGenealiases: CDCBM5 · TUBB · TUBB2
Q-omics provides the consensus-scored TUBB2A profile across patient tissues and cancer cell-line models. TUBB2A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TUBB2A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TUBB2A protein abundance shows 37,380 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where TUBB2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBB2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBB2A survival associations across molecular data types. TUBB2A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBB2A RNA expression–survival associations across cancer types. High TUBB2A expression shows unfavorable associations in ACC, MESO, BLCA, LGG, STAD and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TUBB2A RNA expression.
This table summarizes TUBB2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBB2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBB2A shows lower tumor expression in KIRC, KICH and UCEC and higher tumor expression in LUAD, LIHC and LUSC. The KIRC box plot shows higher TUBB2A RNA expression in normal versus tumor tissue (log2 FC = −0.993, t-test p < 0.001).
This table shows molecular features associated with TUBB2A in patient tissues and cancer cell lines. In patient samples, TUBB2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBB2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
